Scarica l'app Stockscreener
5.95
3.41%
-0.21
Dopo l'orario di chiusura:
5.95
Precedente Chiudi:
$6.16
Aprire:
$6.08
Volume 24 ore:
202.18K
Relative Volume:
0.60
Capitalizzazione di mercato:
$192.13M
Reddito:
$4.06M
Utile/perdita netta:
$-50.22M
Rapporto P/E:
-3.6762
EPS:
-1.6185
Flusso di cassa netto:
$-25.37M
1 W Prestazione:
-7.61%
1M Prestazione:
+42.34%
6M Prestazione:
+7.89%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.67
$6.30
Intervallo di 1 settimana:
$5.67
$6.75
Portata 52W:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
5.95 | 198.91M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
482.08 | 183.60B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
176.11 | 127.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
550.82 | 44.71B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.05 | 38.38B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
371.93 | 37.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings: EPS Surprises to the Upside During Pre‑Revenue Phase - thelegaladvocate.com
Earnings call transcript: Insight Molecular Diagnostics’ Q1 2026 performance and strategic outlook - Investing.com Australia
Insight Molecular Diagnostics Balances Progress and Cash Burn - TipRanks
Insight Molecular Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - Yahoo Finance
BTIG reiterates Neutral on Insight Molecular stock amid FDA review By Investing.com - Investing.com Nigeria
BTIG reiterates Neutral on Insight Molecular stock amid FDA review - Investing.com India
Insight Molecular Q1 2026 Earnings Call Transcript - Sahm
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call H - GuruFocus
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - The Manila Times
Insight Molecular Diagnostics (IMDX) Sees Positive Engagement wi - GuruFocus
Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M - MSN
Insight Molecular Diagnostics (IMDX) Q1 2026 Earnings: EPS not d - GuruFocus
Insight Molecular Diagn 1Q Rev $32,000 >IMDX - Moomoo
Insight Molecular Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Insight Molecular Diagnostics Q1 2026 sees stock rise 2.41% - Investing.com Australia
IMDX Q1 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics Inc Q1 Net Income USD -4.29 Million - TradingView
Insight Molecular Diagn 1Q Loss/Shr 12c >IMDX - Moomoo
Insight Molecular Diagnostics : Investor Deck (imdx investor presentation may 2026) - marketscreener.com
Insight Molecular Diagnostics Q1 loss narrows as costs drop - TradingView
Insight Molecular Diagnostics: Q1 Earnings Snapshot - GreenevilleSun.com
Insight Molecular Diagnostics (NASDAQ: IMDX) Q1 2026 revenue collapses to $32K as losses narrow - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[8-K] Insight Molecular Diagnostics Inc. Reports Material Event - Stock Titan
[8-K/A] Insight Molecular Diagnostics Inc. Amends Material Event Report - Stock Titan
Press Release: IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - Moomoo
Insight Molecular Diagnostics Inc. Q1 earnings preview - MSN
MSN Money - MSN
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Number of shareholders of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
iMDx will post quarterly results May 13, then take investor questions live - Stock Titan
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS), Pfizer (PFE) and Travere Therapeutics (TVTX) - The Globe and Mail
iMDx to Release First Quarter 2026 Results on May 13, 2026 - Yahoo Finance
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.50%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):